At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 751 enrolled
Drug / intervention
ASP2151 +1 moredrug
Likely dose
ASP2151 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Study of ASP2151 in Herpes Zoster Patients- A Double-blind, Valaciclovir-controlled Study
In Brief
A Phase 3 clinical trial evaluating ASP2151 and valaciclovir for Herpes Zoster. Completed, enrolled 751 participants across 3 sites.
Detailed Summary
To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedOct 2013
Primary CompletionJul 2015
Study CompletionJul 2015
TodayJul 2026
First PostedOct 10, 2013
Enrollment StartAug 1, 2013
Primary CompletionJul 1, 2015
Study CompletionJul 10, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.7 years ago
Interventions
ASP2151drug
200 mg once daily or 400 mg once daily
valaciclovirdrug
1000 mg three times daily